Resource Logo
Reuters New Media

Europe recommends approving Schering-Plough drug




 

NEW YORK, Oct 18 (Reuters) - Schering-Plough Corp. SGP.N said an advisory panel to Europe's drug regulators recommended approving the company's Caelyx drug as a stand-alone therapy for breast cancer patients who have an increased risk of heart attacks.

The Committee for Proprietary Medicinal Products, the main advisory body to the European Commission, which is charged with approving or rejecting the drug, issued a "positive opinion" recommending approval of Caelyx, Schering-Plough said.

Caelyx is already marketed in the 15-nation European Union for the treatment of advanced ovarian cancer in women who have failed the standard platinum-based therapy. The drug is also sold as a treatment for an AIDS-related skin disorder known as Kaposi's sarcoma.

Schering-Plough, which is based in Kenilworth, New Jersey, has exclusive non-U.S. licensing rights to the drug, except in Japan and Israel, through a distribution agreement with a subsidiary of Johnson & Johnson JNJ.N .

The drug is marketed in the United States under the brand name Doxil by Johnson & Johnson.



 


Copyright © 2002 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in October 18, 2002. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.